Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective March 6, 2009, the board of directors of XenaCare Holdings, Inc. (the "Registrant" or the "Company") increased the number of seats on the Company's board of directors from four to five and appointed Rik Deitsch to fill the vacancy created by the additional seat. Mr. Deitsch shall serve as a director until the Company's next annual meeting of shareholders and until his successor is duly elected and qualified.

Mr. Deitsch holds degrees in Chemistry and Biochemistry. He is currently an Adjunct Professor at Florida Atlantic University and works with the development of pharmaceutical products in the research and development departments at Duke University and the Cleveland Clinic. Mr. Deitsch also teaches Continuing Educational Classes for educational updates for doctors at various institutions. Mr. Deitsch has developed nutrition products that have been licensed to major corporations. He is a published author and worldwide lecturer. He currently presents papers and speaks to the medical field and pharmaceutical companies at seminars and conferences. In addition to his duties as a member of the Company's board of directors, he will advise the Company on product development, concentrating on developing the scientific rationale for products that are beneficial to a broad range of consumers.

---